Amgen’s (AMGN) Neutral Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Amgen (NASDAQ:AMGN) in a research note published on Tuesday,Benzinga reports. They currently have a $400.00 price target on the medical research company’s stock.

Several other research analysts have also recently issued reports on the stock. Citigroup raised their target price on shares of Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Piper Sandler upped their price target on shares of Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. TD Cowen increased their price target on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Mizuho raised their price target on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a report on Tuesday, August 18th. Finally, Bank of America boosted their price objective on shares of Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $381.68.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $382.47 on Tuesday. The stock’s 50-day moving average is $400.31 and its 200 day moving average is $367.85. The stock has a market cap of $206.77 billion, a price-to-earnings ratio of 23.77, a P/E/G ratio of 2.82 and a beta of 0.43. Amgen has a 1-year low of $269.77 and a 1-year high of $447.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the firm posted $6.02 earnings per share. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts anticipate that Amgen will post 22.97 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s payout ratio is presently 62.65%.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last 90 days. Company insiders own 0.85% of the company’s stock.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently bought and sold shares of AMGN. California State Teachers Retirement System lifted its stake in shares of Amgen by 36,047.1% in the second quarter. California State Teachers Retirement System now owns 298,255,793 shares of the medical research company’s stock worth $108,004,388,000 after buying an additional 297,430,677 shares in the last quarter. Norges Bank purchased a new position in Amgen in the 4th quarter worth approximately $2,164,162,000. Bank of America Corp DE purchased a new position in Amgen in the 2nd quarter worth approximately $1,831,903,000. Capital World Investors lifted its position in Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after acquiring an additional 4,302,237 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Amgen by 1,102.7% in the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after acquiring an additional 2,514,254 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported that the Imdelltra-Imfinzi combination improved survival outcomes in a late-stage study of first-line extensive-stage small-cell lung cancer. The results could expand Imdelltra’s addressable market and strengthen the long-term growth outlook for Amgen’s oncology portfolio. AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
• Positive Sentiment: TD Cowen and Piper Sandler maintained Buy ratings, while a Seeking Alpha analysis upgraded Amgen, arguing that the recent selloff created an attractive entry point. Supportive ratings may help limit downside if the company’s pipeline continues to deliver. TD Cowen Keeps Their Buy Rating on Amgen
• Neutral Sentiment: Amgen announced a Phase 4 trial evaluating Repatha’s impact on coronary plaque, potentially providing additional evidence to support the cardiovascular drug’s use. However, the study is longer-term and is unlikely to materially affect near-term earnings. Amgen’s New Repatha Plaque Trial
• Neutral Sentiment: Analyst views remain mixed: Cantor Fitzgerald and Wells Fargo retained Neutral and Hold ratings, respectively, while Amgen’s healthcare-conference presentations could provide additional details on its pipeline and outlook. Cantor Fitzgerald Reaffirms Neutral Rating for Amgen
• Negative Sentiment: The main pressure came from Novartis’ disappointing trial results, which raised concerns about the broader cholesterol-drug class and weighed on expectations for Amgen’s related pipeline opportunities. Unusually heavy put-option activity also signaled elevated near-term bearish positioning. Amgen Falls as Novartis Trial Failure Clouds Cholesterol Drug Class
• Negative Sentiment: Investors remain concerned that falling Prolia and XGEVA sales from biosimilar competition, combined with continued investment in MariTide, will require margin expansion to justify Amgen’s valuation. Amgen’s Forward Multiple Looks Cheap Until You Price the Margins It Assumes

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.